Bioventix PLC (GB:BVXP)
LSE:BVXP
Want to see GB:BVXP full AI Analyst Report?
Top Page
Bioventix
(LSE:BVXP)
Select Model
Select Model
Rating:75Outperform
Price Target:
1,744.00 p
▼(-3.11% Downside)
Action:Reiterated
Date:12/30/25
The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).
Positive Factors
Conservative balance sheet
Zero reported debt and a conservative balance sheet provide durable financial resilience, lowering solvency risk and preserving flexibility to fund operations, dividends or opportunistic investments from internal resources. High returns on equity reinforce efficient capital use.
Negative Factors
Slowing revenue and FCF momentum
A recent decline in revenue and free cash flow signals weakening operating momentum that, if persistent, can reduce scale benefits, compress absolute profits and limit reinvestment capacity. Sustained top-line weakness could pressure long-term royalty streams and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Zero reported debt and a conservative balance sheet provide durable financial resilience, lowering solvency risk and preserving flexibility to fund operations, dividends or opportunistic investments from internal resources. High returns on equity reinforce efficient capital use.
Read all positive factors
Bioventix (BVXP) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£91.17M
Dividend Yield8.33%
Average Volume (3M)7.85K
Price to Earnings (P/E)12.8
Beta (1Y)0.66
Revenue Growth-8.21%
EPS Growth-5.27%
CountryUK
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.94
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)N/A
Bioventix Business Overview & Revenue Model
Company Description
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical a...
How the Company Makes Money
Bioventix primarily makes money by licensing and supplying monoclonal antibody reagents to major in-vitro diagnostics and assay manufacturers. Its core revenue model is business-to-business: Bioventix develops proprietary antibodies against specif...
Bioventix Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.54M | 13.12M | 13.61M | 12.82M | 11.72M | 10.93M |
| Gross Profit | 11.53M | 11.92M | 12.68M | 11.86M | 10.87M | 9.98M |
| EBITDA | 9.54M | 10.17M | 10.74M | 10.20M | 9.42M | 8.22M |
| Net Income | 7.44M | 7.58M | 8.10M | 8.37M | 7.67M | 6.73M |
Balance Sheet | ||||||
| Total Assets | 13.03M | 12.86M | 13.73M | 13.28M | 13.12M | 12.91M |
| Cash, Cash Equivalents and Short-Term Investments | 5.30M | 5.08M | 6.00M | 5.72M | 6.13M | 6.49M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.99M | 1.31M | 1.73M | 1.22M | 1.30M | 1.09M |
| Stockholders Equity | 11.04M | 11.55M | 12.00M | 12.06M | 11.82M | 11.82M |
Cash Flow | ||||||
| Free Cash Flow | 7.92M | 7.01M | 8.33M | 7.89M | 7.55M | 6.11M |
| Operating Cash Flow | 7.96M | 7.03M | 8.34M | 7.90M | 7.56M | 6.37M |
| Investing Cash Flow | -32.75K | 173.16K | 186.06K | 90.51K | -11.76K | -259.83K |
| Financing Cash Flow | -7.76M | -8.12M | -8.25M | -8.30M | -7.92M | -7.69M |
Bioventix Technical Analysis
Positive
1800.00
Price Trends
1705.60
Positive
1625.63
Positive
1805.14
Negative
Market Momentum
14.22
Negative
57.29
Neutral
84.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1800 is above the 20-day moving average (MA) of 1667.25, above the 50-day MA of 1705.60, and below the 200-day MA of 1805.14, indicating a neutral trend. The MACD of 14.22 indicates Negative momentum. The RSI at 57.29 is Neutral, neither overbought nor oversold. The STOCH value of 84.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.
Bioventix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £91.17M | 12.82 | 65.83% | 8.33% | -8.21% | -5.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £341.94M | -8.36 | -2929.47% | ― | ― | ― | |
44 Neutral | £15.64M | -9.26 | -210.32% | ― | -11.43% | 23.40% | |
43 Neutral | £81.30M | -4.83 | -116.21% | ― | 81.46% | -15.88% | |
40 Underperform | £7.08M | -0.17 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £18.14M | -5.08 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:BVXP
Bioventix
1,745.00
-759.68
-30.33%
GB:AVCT
Avacta Group plc
73.00
41.00
128.13%
GB:OBD
Oxford BioDynamics
0.17
-0.23
-57.69%
GB:FAB
Fusion Antibodies Plc
12.50
6.20
98.41%
GB:4BB
4basebio UK Societas
525.00
-460.00
-46.70%
GB:APTA
Aptamer Group Plc
0.53
0.21
64.06%
Bioventix Corporate Events
DividendsRegulatory Filings and Compliance
Bioventix CFO Increases Stake Through Dividend Reinvestment Plan
Positive
Apr 28, 2026
Bioventix has disclosed a director dealing after Chief Financial Officer Bruce Hiscock acquired 66 ordinary shares in the company at 1,679 pence each through a dividend reinvestment plan. Following this transaction, Hiscock’s total beneficia...
Business Operations and StrategyExecutive/Board Changes
Bioventix Ties Executive Share Options to Neurological Test Revenue Milestone
Positive
Apr 20, 2026
Bioventix plc has granted share options to chief executive Peter Harrison and chief financial officer Bruce Hiscock under its 2020 Share Option Plan, with exercise prices set at £17.75. Following the awards, Harrison holds options over 52,622...
Regulatory Filings and Compliance
Bioventix Chairman Increases Stake with Share Purchase
Positive
Apr 13, 2026
Bioventix has announced that its non-executive chairman, Ian Nicholson, has purchased 1,000 ordinary shares in the company at a price of 1,848 pence per share. The transaction, conducted on 10 April 2026 on the London Stock Exchange’s AIM ma...
Other
Bioventix CEO Increases Stake After Share Purchases with Spouse
Positive
Apr 8, 2026
Bioventix has disclosed that chief executive Peter Harrison and his wife Abigail have each purchased 1,065 ordinary shares in the company at 1,849 pence per share on 8 April 2026. Following these transactions, Harrison and his closely associated p...
Regulatory Filings and Compliance
Bioventix CFO Increases Personal Stake with Share Purchase
Positive
Apr 2, 2026
Bioventix plc reported that its Chief Financial Officer, Bruce Hiscock, purchased 126 ordinary shares in the company on 2 April 2026 at a price of 1,622 pence per share. Following this transaction, Hiscock’s total beneficial holding increase...
Business Operations and StrategyDividendsFinancial Disclosures
Bioventix Leans on Neuro Antibodies as Interim Profits Hold Steady
Positive
Mar 30, 2026
Bioventix reported a modest dip in interim revenue to £6.16m and profit before tax to £4.85m for the six months to 31 December 2025, while maintaining a strong cash position of £5.3m and holding its interim dividend at 70p per share...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.